Login / Signup

Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations.

Karolina KnapKonrad KwiecieńKatarzyna Reczyńska-KolmanElżbieta Pamuła
Published in: Regenerative biomaterials (2022)
Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and side effects. On the other hand, there are several difficulties in obtaining a formulation that would meet all the criteria related to physicochemical, aerodynamic and biological properties, which is the reason why only very few of the investigated systems can reach the clinical trial phase and proceed to everyday use as a result. Therefore, we focused on powders consisting of polysaccharides, lipids, proteins or natural and synthetic polymers in the form of microparticles that are delivered by inhalation to the lungs as drug carriers. We summarized the most common trends in research today to provide the best dry powders in the right fraction for inhalation that would be able to release the drug before being removed by natural mechanisms. This review article addresses the most common manufacturing methods with novel modifications, pros and cons of different materials, drug loading capacities with release profiles, and biological properties such as cytocompatibility, bactericidal or anticancer properties.
Keyphrases
  • drug delivery
  • clinical trial
  • drug induced
  • adverse drug
  • pulmonary hypertension
  • emergency department
  • randomized controlled trial
  • cancer therapy
  • phase ii
  • bone marrow
  • study protocol
  • drug release